wayground logo

Free Printable Worksheets

Font size

S
M
L
XL
Worksheets

Module 4 Biopharm Green 1-100

Total questions: 100

Worksheet time: 50mins

Name
Class
Date
1.
The termination of action of a drug is determined by:
a)
a. excretion of intact active molecule
b)
b. excretion of inactive molecule
c)
c.  tissue redistribution
d)
d. a & c
2.
Pharmaceutical equivalents are drug products that contain:
a)
a. identical amounts of active drugs
b)
b. identical amounts of inactive ingredients
c)
c. identical amounts of excipients
d)
d. AOTA
3.
The purpose of biotransformation reaction is:
a)
a. deactivate the drug
b)
b. preserve the drug from destruction
c)
c.  promote the elimination of the inactive drug
d)
d. a & c
4.
The advantage of sublingual/buccal administration is
a)
a. no occurrence of gastrointestinal degradation
b)
b. drug directly in the circulation
c)
c. does not pass to the liver
d)
d. a & c
5.
In LADMER system, L stands for liberation as the first step which determines the ff. aspects, EXCEPT:
a)
a. onset of action
b)
b. type of preparation
c)
c.  rate of absorption
d)
d. bioavailability
6.
Factor that contribute to patient’s difference in drug concentration in the body except;
a)
a. body weight
b)
b. obesity
c)
c.  age
d)
d. climate
7.
The effect of reduced particle size of a drug s:
a)
a. increase absorption
b)
b. increased disintegration
c)
c. increased hardness
d)
d. all of them
8.
A cause of patient to patient variability of time course of the drug in the plasma is:
a)
a. Disease
b)
b. concomitant dug therapy
c)
c. genetic origin
d)
d. all
9.
Dissolution rate tests can be used to predict bioavailability if:
a)
a. dissolved drug remains free in the GIT
b)
b. dissolved drug is decomposed in the GIT
c)
c. drug is hydrolyzed in the GIT
d)
d. all of them
10.
Elimination half-life of a drug is the time in hours needed to reduce drug concentration to:
a)
a. half of the parent drug
b)
b. one fourth of the initial dose
c)
c. all or taken dose
d)
d. a & b
11.
Tmax means:
a)
a. time of great solubility of the drug
b)
b. peak height concentration
c)
c. time of peak concentration
d)
d. AUC values
12.
The difference in bioavailability of a drug product of the same therapeutic agent is due to:
a)
a. difference in formulative ingredients
b)
b. difference in packaging
c)
c. difference in methods of manufacture
d)
d. all of the above
13.
The ultimate evaluation of dosage forms or delivery system is on:
a)
a. disintegration time
b)
b. thickness
c)
c. clinical effectiveness
d)
d. taste
14.
A rate limiting factor in the dissolution of drugs is:
a)
a. disintegration of the tablet
b)
b. thickness
c)
c. content uniformity
d)
d. local effect
15.
15. To generally increase the solubility of a poorly soluble drug in an aqueous medium, the process is:
a)
a. complexation
b)
b. adsorption
c)
c. prepare into a derivative
d)
d. a & c
16.
The ionization constant of a drug is important in bioavailability since it determines the ff. except;
a)
a. its aqueous solubility
b)
b. dissolution rate
c)
c. pH of the medium
d)
d. its rate of transport across lipoidal layers
17.
Which of the crystal forms give the best dissolution rate?
a)
a. meta-stable polymorph
b)
b. amorphous
c)
c. stable polymorph
d)
d. a & c
18.
For faster absorption, what type of diluent or filler is needed if the drug is hydrophobic?
a)
a. hydrophilic
b)
b. water repellant
c)
c. ampiphilic
d)
d. b & c
19.
The route of administration which will by-pass the GIT degradation and hepatic metabolism is:
a)
a. intravenous injection
b)
b. sublingual
c)
c. buccal
d)
d. b & c
20.
A branch of science which deals with the changes of drug concentration and its metabolites in the human or animal body after administration is:
a)
a. bioavailability
b)
b. pharmacokinetics
c)
c. biopharmaceutics
d)
d. a & b
21.
The first step which determines the onset of action, rate of absorption, availability is:
a)
a. liberation
b)
b. distribution
c)
c. excretion
d)
d. absorption
22.
The integral of drug level over time from zero to infinity is:
a)
a. biologic half life
b)
b. AUC
c)
c. bioavailability
d)
d. biopharmaceutics
23.
A site in the biophase to which drug molecules can be bound is:
a)
a. fluid compartment
b)
b. unit membrane
c)
c. receptor
d)
d. none of the above
24.
A branch of science which deals with physical and chemical properties of the drug substance, the dosage form, and the biological effectiveness of a drug or drug product upon administration is:
a)
a. pharmacology
b)
b. pharmacokinetics
c)
c. biopharmaceutics
d)
d. pharmacy
25.
The ability of a substance to exist in different crystalline forms is:
a)
a. amphoterism
b)
b. salting in
c)
c. polymorphism
d)
d. precipitation
26.
Differences in bioavailability are most frequently observed with drugs administered by which of the following route?
a)
a. subcutaneous
b)
b. intravenous
c)
c. oral
d)
d. sublingual
27.
Which of the ff. factors delays transmit time?
a)
a. increasing viscosity
b)
b. liquid diet
c)
c. water
d)
d. b & c
28.
S drug can exert its pharmacologic effect only when it is:
a)
a. protein bound
b)
b. protein unbound
c)
c. free drug
d)
d. b & c
29.
The principal site of drug metabolism is:
a)
a. kidney
b)
b. muscle tissue
c)
c. gut wall
d)
d. liver
30.
The mechanism for drug excretion via the kidney is:
a)
a. active transport
b)
b. glomerular filtration
c)
c. pinocytosis
d)
d. passive diffusion
31.
The major plasma protein involved in the distribution of weak acid is:
a)
a. albumin
b)
b. glycoprotein
c)
c. glycine
d)
d. gelatin
32.
The rate at which the drug appears in the bloodstream is known as:
a)
a. biopharmaceutics
b)
b. AUC
c)
c. bioavailability
d)
d. biologic half life
33.
The dose size required to maintain effectiveness or therapeutic concentration according to the dosage regimen is:
a)
a. priming dose
b)
b. maintenance
c)
c. loading dose
d)
d. any of the above
34.
34. An inactive or much less active substance which is transformed to active drug in the body is:
a)
a. dosage form
b)
b. drug product
c)
c. aspirin
d)
d. prodrug
35.
Studies of bioavailability are generally not required when:
a)
a. drug is intended solely for IV use
b)
b. the drug is for local therapeutic use
c)
c. the drug is an oral product not required to be absorbed
d)
d. all of the above
36.
Gastric emptying is showed by the ff. except:
a)
a. a vigorous exercise
b)
b. fatty foods
c)
c. hot meals
d)
d. hunger
37.
The ratio of the concentration of a drug in two immiscible phases is known as the
a)
a. concentration ratio
b)
b. miscibility ratio
c)
c. partial miscibility
d)
d. lipid/ water partition coefficient
38.
The metabolism of drugs generally results in:
a)
a. less acidic compounds
b)
b. more acidic compounds
c)
c. more polar compounds
d)
d. compounds having a higher oil/water partition coefficient
39.
Liberation is a process controlled by:
a)
a. age of the patient
b)
b. characteristics of the drug
c)
c.  both a and b
40.
Reabsorption of drugs and its metabolites occurs in the:
a)
a. kidney
b)
b. intestines
c)
both a and b
d)
none of the above
41.
Which of the ff factors affect the dissolution in the lipid membrane of the lipid soluble unionized fluid compartment:
a)
a. pH
b)
b. pKa
c)
c. lipid/water partition coefficient
d)
d. all of the above
42.
The prerequisites of the binding of a drug to a receptor are as follows, EXCEPT
a)
a. chemical reactivity
b)
b. electronic distribution
c)
c. absence of functional group
d)
d. none of the above
43.
The following mechanism of absorption required the presence of drug in aqueous solution, EXCEPT:
a)
a. passive diffusion
b)
b. convective transport
c)
c. facilitated transport
d)
d. pinocytosis
44.
A type of transport whereby drug molecules dissolved in aqueous medium at the absorption site move along with the liquid through the pore.
a)
a. active transport
b)
b. ion pair transport
c)
c. convective transport
d)
d. facilitated transport
45.
The ff. compounds are absorbed via convective transport EXCEPT:
a)
a. ions of opposite charge of pore lining
b)
b. ionized sulfonamides
c)
c. weak organic acids
d)
d. NOTA
46.
When a substance is half ionized at a certain pH, its pKa is
a)
a. greater than pH
b)
b. less than the pH
c)
c. equal to pH
d)
d. negligible as compared to the pH
47.
The Noyes-Whitney Equation determines
a)
a. particle size measurement
b)
b. actual drug solubility
c)
c. dissolution constant
d)
d. dissolution rate
48.
48. Differences in bioavailability are most frequently observed with drugs administered by which of the ff routes?
a)
a. SQ
b)
b. IV
c)
c. oral
d)
d. SL
49.
49. When considering drug transport, a “passive transport process” implies that:
a)
a. all of the drug will pass from one compartment to another
b)
b. the drug is highly soluble
c)
c. the net transfer of drug is from an area of higher concentration to an area of low concentration
d)
d. the net transfer of drug is from an area of lower concentration to an area of higher concentration
50.
The rate of diffusion of drugs across biological membranes is most commonly:
a)
a. independent on the concentration gradient
b)
b. directly proportional to the concentration gradient
c)
c. dependent on the availability of carrier substance
d)
d. dependent on the route of administration
51.
In general, various oral dosage forms can be ranked in which of the ff expected order of availability (fastest to slowest)
a)
a. aqueous solution, capsule, tablet, powder, coated tablet, suspension
b)
b. capsule, tablet, coated tablet, powder, suspension, aqueous solution
c)
c. aqueous solution, suspension, powder, capsule, tablet, coated tablet
d)
d. suspension, aqueous solution, powder, capsule, coated tablet, tablet
52.
The rectal route of administration may be preferred over the oral route for some drug because:
a)
a. the drug does not have to be absorbed
b)
b. absorption is predictable and complete
c)
c. a portion of the absorbed drug does not pass through the liver before entering the systemic solution
d)
d. the dissolution process is involved
53.
Drugs that are poorly lipid soluble or extensively ionized at the pH of the blood generally
a)
a. penetrate the CNS very slowly and may essentially be eliminated from the body before a significant concentration in CNS is reached
b)
b. achieve adequate CNS concentration only if given IV
c)
c. must be metabolized to a more polar form before they can gain access to the CNS
d)
d. can gain access to the CNS if other drugs are used to modify the blood pH
54.
The ff statements are true, EXCEPT
a)
a. amorphous form is more soluble than that of the crystalline form
b)
b. the amorphous form has a higher dissolution rate than that of crystalline form
c)
c. the crystalline form requires a higher amount of energy to free molecule of the drug from it than does the amorphous form
d)
d. the amorphous form requires a higher amount of energy to free molecule of the drug from it than does the crystalline form
55.
These are addition compounds of drug and organic solvents:
a)
a. hydrates
b)
b. solvates
c)
c. polymorphs
d)
d. NOTA
56.
The displacement of drug from protein binding site causes:
a)
a. decrease in the intensity of the pharmacological response
b)
b. decrease in the intensity of side effects
c)
c. toxicity
d)
d. all of the above
57.
The major pathway of excretion
a)
a. via the liver
b)
b. via the kidney
c)
c. via the circulation system
d)
d. via the large intestines
58.
Which of the ff factors tend to alter the rate of absorption?
a)
a. age
b)
b. disease
c)
c. both a and b
d)
d. NOTA
59.
Which of the ff properties of surfactants tend to increase the rate of dissolution?
a)
a. surface tension lowering effect
b)
b. production of micelles with the parent drug
c)
c. absence of peptizing action
d)
d. AOTA
60.
Which of the ff events modify drug absorption?
a)
a. physiological constituents of digestion
b)
b. Drug interaction
c)
c. certain physiologic state
d)
d. AOTA
61.
The process that determines absolute bioavailability are the first pass effect and:
a)
a. absorption
b)
b. liberation
c)
c. distribution
d)
d. metabolism
62.
A relative bioavailability study is necessary when there is:
a)
a. a change in galenic of the drug
b)
b. a change in the method of manufacture
c)
c. a change in the means of preservation
d)
d. AOTA
63.
In organs and tissues that are well perfused:
a)
a. distribution is lower
b)
b. distribution is faster
c)
c. distribution rate is negligible
d)
d. NOTA
64.
The ff pathological states influence the volume of distribution, EXCEPT
a)
a. renal disease
b)
b. hepatic disease
c)
c. cardiac insufficiency
d)
d. vertigo
65.
Renal clearance depends on:
a)
a. urinary pH
b)
b. glomerular filtration
c)
c. absorption
d)
d. distribution
66.
The breakdown of ingested foreign compounds to simpler structures:
a)
a. catabolism
b)
b. anabolism
c)
c. homeostasis
d)
d. NOTA
67.
The magnitude of bile production depends on
a)
a. type of food
b)
b. the amount of bile emptied
c)
c. enzyme activity
d)
d. AOTA
68.
Biliary excretion principle
a)
a. through the bile duct into the duodenum
b)
b. major portion of the bile is excreted
c)
c. as metabolite
d)
d. any of the above
69.
Biotransformation of a drug takes place in the liver in the presence of:
a)
a. energy from the body
b)
b. enzymes which acts as catalysts
c)
c. substance is destroyed in the liver
d)
d. a and c
70.
Due to their anatomical structure, the organ which is the most important site of drug absorption is
a)
a. large intestine
b)
b. stomach
c)
c. small intestine
d)
d. mucous membrane of the mouth
71.
A factor determining the activity of a drug:
a)
a. formulation of a dosage form
b)
b. individual
c)
c. dose
d)
d. a&b
72.
Factor affecting difference between loading and maintenance doses
a)
a. half life of the drug
b)
b. effectiveness of the dose
c)
c. adverse effect
d)
d. b & c
73.
Factor affecting gastric emptying time of a drug
a)
a. age of a person
b)
b. time of the day
c)
c. body posture
d)
d. all of them
74.
Application of clinical pharmaceutics as to management of individual patient is the:
a)
a. safety
b)
b. overdosage
c)
c. therapeutic
d)
d. a and c
75.
If the extent and rate of absorption is similar to the standard drug, it has achieved the:
a)
a. bioequivalence of the drug product
b)
b. pharmaceutical equivalence
c)
c. pharmaceutical alternative
d)
d. a and b
76.
The time in hours necessary to reduce the drug concentration in the blood, the plasma, or serum, to half its original concentration after equilibrium is reached:
a)
a. biological half life
b)
b. AUC
c)
c. bioavailability
d)
d. a & b
77.
The hypothetical plasma volume in ml of the unmetabolized drug which is cleared in one minute via the kidney:
a)
a. volume of distribution
b)
b. renal clearance
c)
c. total clearance
d)
d. AUC
78.
An entity which can be described by a definite volume and a concentration of drug contained in that volume:
a)
a. compartment
b)
b. serum level
c)
c. receptor
d)
d. bloodstream
79.
79. A cell or cell compartment where the final interaction between drug and receptor takes place
a)
a. receptor
b)
b. biophase
c)
c. unit membrane
d)
d. muscle
80.
Drugs that are absorbed in the GIT are generally:
a)
a. absorbed into the portal of circulation and pass through the liver before entering the general circulation
b)
b. filtered from the blood by the kidney, then reabsorbed into the general circulation
c)
c. not affected by the liver enzymes
d)
d. stored in the liver
81.
The volume of distribution of a drug is
a)
a. mathematical relationship between the total amount of drug in the body and the concentration of drug in the blood
b)
b. a measure of an individual’s blood volume
c)
c. an expression of total body volume
d)
d. a measure of the individual fluid volume
82.
The biologic half life of many drugs is often prolonged in new born infants because of:
a)
a. a higher decrease of protein binding
b)
b. microsomal enzyme induction
c)
c. more complete absorption of drugs
d)
d. incompletely developed enzyme system
83.
Which of the ff factors increase the rate of gastric emptying?
a)
a. fats
b)
b. increasing
c)
c. anticholinergic agents
d)
d. NOTA
84.
The force of attraction which binds drugs to albumin:
a)
a. Van der Waals
b)
b. hydrophobic bond
c)
c. hydrogen bond
d)
d. AOTA
85.
The metabolism and/or the elimination of a drug by gastrointestinal and hepatic drug metabolizing enzyme which can occur after oral administration of a drug:
a)
a. first pass metabolism
b)
b. biliary recycling
c)
c. hepatic clearance
d)
d. BUN
86.
The administration of the same dose of active ingredient in different galenic forms:
a)
a. always leads to the same therapeutic effect
b)
b. does not necessarily lead to the same therapeutic effect
c)
c. always lead to different therapeutic effect
d)
d. NOTA
87.
Possible approaches to measure the bioavailability
a)
a. blood level data
b)
b. urinary excretion data
c)
c. clinical data
d)
d. AOTA
88.
Drugs that are usually released much more slowly from fat because
a)
a. fat has relatively limited blood supply
b)
b. drugs are more fat bound than plasma bound
c)
c. fat bound drugs to itself more
d)
d. AOTA
89.
Cumulative urinary excretion is often used in pharmacokinetic and clinical studies in man and animals to learn about the disposition of the drugs and to determine the ff.:
a)
a. Ka
b)
b. fraction of drug absorbed
c)
c. % of drug absorbed
d)
d. AOTA
90.
The theory which states that the cell membrane is made up of a bi-lipid layer and fluid protein molecules interspersed in between the 2 layers of lipid
a)
a. fluid-mosaic
b)
b. Monsanto
c)
c. Davidson
d)
d. Nicholson
e)
e. NOTA
91.
It is the loss of the drug from the central compartment due to transfer into other compartments and or elimination or metabolism
a)
a. dosage regimen
b)
b. disposition
c)
c. depot phase
d)
d. creatinine clearance
e)
e. circadian rhythm
92.
Obtained when the drug product is administered at the site where the pharmacological response is desired and when the drug released from the product acts by the adsorption to the skin or mucosa or penetrates into the skin or mucosa, but does not enter the systemic circulation or lymphatic system.
a)
a. systemic effect
b)
b. local effect
c)
c. mean transit time
d)
d. micro constants
93.
Maintenance of a steady state which characterize the internal environment of the healthy organism.
a)
a. steady state
b)
b. depot phase
c)
c. homeostasis
d)
d. maintenance dose
94.
The speed of blood perfusion in an organ, usually expressed in ml/100g organ weight/min
a)
a. accumulation
b)
b. bioavailability
c)
c. blood flow rate
d)
d. absorption
95.
Those drugs which the pharmacological actions depend directly on the chemical structure of the drug.
a)
a. structure specific drugs
b)
b. structure non specific
c)
c. drug agonist
d)
d. NOTA
96.
If drug A is more lipophilic than drug B, then;
a)
a. drug A will be better distributed than drug B
b)
b. drug B will be better distributed than drug A
c)
c. drug agonist
d)
d. NOTA
97.
Drugs of low solubility may be brought into solution by the use of:
a)
a. solvent
b)
b. vehicle
c)
c. surfactants
d)
d. AOTA
98.
A type of antagonism whereby the agonist and antagonist bind to different receptor and have opposite pharmacologic actions:
a)
a. partial antagonism
b)
b. non-equilibrium antagonism
c)
c. non-competitive antagonism
d)
d. competitive antagonism
99.
The LADME system is employed in:
a)
a. the development of new active compounds
b)
b. the determination of effective dose size
c)
c. the adjustment of dosage regimen
d)
d. AOTA
100.
A type of antagonism whereby the antagonist forms irreversible receptor binding:
a)
a. partial antagonism
b)
b. non-equilibrium antagonism
c)
c. non-competitive antagonism
d)
d. competitive antagonism